We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+1.34%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$42.2B
AUM Growth
-$1.23B
(-2.8%)
Cap. Flow
-$952M
Cap. Flow
% of AUM
-2.26%
Top 10 Holdings %
Top 10 Hldgs %
14.57%
Holding
2,171
New
150
Increased
772
Reduced
960
Closed
152
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$156M |
| 2 |
Prologis
PLD
|
+$150M |
| 3 |
Chevron
CVX
|
+$109M |
| 4 |
Qualcomm
QCOM
|
+$101M |
| 5 |
Paycom
PAYC
|
+$90.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
+$230M |
| 2 |
Kimberly-Clark
KMB
|
+$160M |
| 3 |
Stanley Black & Decker
SWK
|
+$130M |
| 4 |
Paychex
PAYX
|
+$113M |
| 5 |
Dominion Energy
D
|
+$105M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.81% |
| 2 | Healthcare | 17.11% |
| 3 | Financials | 12.73% |
| 4 | Industrials | 9.87% |
| 5 | Consumer Discretionary | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
YMAB
1301
DELISTED
Y-mAbs Therapeutics
YMAB
| $537K | ﹤0.01% |
44,474
-91
| -0.2% | -$1.23K |
|
1302
ESAB
ESAB
$4.13B
| $537K | ﹤0.01% |
5,688
-23,943
| -81% | -$2.49M |
|
1303
Iridium Communications
IRDM
$5.01B
| $535K | ﹤0.01% |
20,085
+4,085
| +26% | +$115K |
|
1304
Louisiana-Pacific
LPX
$4.57B
| $533K | ﹤0.01% |
6,471
-662
| -9% | -$55.3K |
|
|
LPRO
1305
DELISTED
Open Lending Corp
LPRO
| $532K | ﹤0.01% |
95,418
+8,010
| +9% | +$46.1K |
|
1306
Acco Brands
ACCO
$392M
| $529K | ﹤0.01% |
112,625
-3,317
| -3% | -$16.5K |
|
1307
Genworth Financial
GNW
$3.81B
| $522K | ﹤0.01% |
86,503
-914,313
| -91% | -$5.69M |
|
1308
Puma Biotechnology
PBYI
$485M
| $522K | ﹤0.01% |
160,233
-691
| -0.4% | -$3.03K |
|
1309
NextCure
NXTC
$27.6M
| $521K | ﹤0.01% |
27,284
| – | – |
|
1310
Acadia Healthcare
ACHC
$2.62B
| $520K | ﹤0.01% |
7,699
-2,121
| -22% | -$148K |
|
1311
American Airlines Group
AAL
$8.41B
| $519K | ﹤0.01% |
45,800
-11,768
| -20% | -$155K |
|
1312
Agree Realty
ADC
$8.52B
| $513K | ﹤0.01% |
8,285
-184
| -2% | -$10.9K |
|
1313
Badger Meter
BMI
$3.7B
| $511K | ﹤0.01% |
2,742
-1
| -0% | -$183 |
|
1314
MDU Resources
MDU
$3.92B
| $511K | ﹤0.01% |
36,734
-6,167
| -14% | -$85.2K |
|
1315
DXP Enterprises
DXPE
$2.85B
| $502K | ﹤0.01% |
10,962
+888
| +9% | +$44.8K |
|
1316
Sonoco
SON
$4.79B
| $499K | ﹤0.01% |
9,847
-466
| -5% | -$26.9K |
|
1317
Pinnacle Financial Partners Inc
PNFP
$14.5B
| $499K | ﹤0.01% |
6,237
-1,805
| -22% | -$144K |
|
1318
NewMarket
NEU
$8.2B
| $496K | ﹤0.01% |
962
-338
| -26% | -$188K |
|
1319
Beam Therapeutics
BEAM
$2.39B
| $488K | ﹤0.01% |
+20,839
| New | +$512K |
|
1320
Diamondback Energy
FANG
$54.5B
| $487K | ﹤0.01% |
2,432
+1,668
| +218% | +$331K |
|
1321
Warner Music
WMG
$14.8B
| $485K | ﹤0.01% |
+15,823
| New | +$508K |
|
1322
Black Hills Corp
BKH
$5.38B
| $481K | ﹤0.01% |
8,841
-3,166
| -26% | -$173K |
|
1323
Exponent
EXPO
$3.23B
| $479K | ﹤0.01% |
5,038
+1,307
| +35% | +$118K |
|
1324
ResMed
RMD
$32.9B
| $476K | ﹤0.01% |
2,486
-134
| -5% | -$27.2K |
|
1325
Glacier Bancorp
GBCI
$5.85B
| $475K | ﹤0.01% |
12,724
-290
| -2% | -$10.8K |
|
Similar funds
Federated Hermes's Q2 2024 Portfolio in Review
As of Q2 2024, Federated Hermes held 2,171 positions worth $42.2B, down 2.8% from $43.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes's Q2 2024 filing shows 150 new, 772 increased, 960 reduced and 152 closed positions. Its largest new stake was Loar Holdings: 729,296 shares worth $39M. The largest sale was Fusion Pharmaceuticals Inc. Common Shares, an estimated $230M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.
- Federated Hermes's largest Q2 2024 buy was Loar Holdings: 729,296 shares worth $39M.
- Federated Hermes added most to Bristol-Myers Squibb in Q2 2024, an estimated $156M increase.
- Federated Hermes's biggest Q2 2024 reduction was Kimberly-Clark, cutting an estimated $160M.
- Federated Hermes fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $230M.
- Federated Hermes's ten largest holdings make up 15% of its $42.2B portfolio in Q2 2024.
- Federated Hermes opened 150 new positions and closed 152 in Q2 2024.
- Federated Hermes's portfolio value fell 2.8% quarter-over-quarter to $42.2B.
Based on Federated Hermes's 13F filing for Q2 2024, filed 8 Aug 2024.